Belgium· BE-AMP-SAM534773-00
Cablivi 10 mg
A caplacizumab product containing caplacizumab, registered in Belgium by Ablynx. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Caplacizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC B01AX07 (caplacizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Caplacizumab · ATC B01AX07
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of caplacizumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Caplacizumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4847.79
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Caplacizumab
- Manufacturer
- Ablynx
- Country
- Belgium (BE)
- ATC code
- B01AX07
- ATC class
- Caplacizumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7725864
- be_apb3908878
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
142 interactions on record for caplacizumab.
Graded by severity as the source publishes them — 72 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Caplacizumab · interactions on record
142 records
- 72 severe
- 70 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Caplacizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayCabliviAblynx NV
- SpainCABLIVI 10 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAblynx
- United KingdomCablivi 10mg powder and solvent for solution for injection vialsSanofi
- IcelandCabliviAblynx NV
- PolandCabliviAblynx NV
- SwedenCablivi 10 mg Pulver och vätska till injektionsvätska, lösningAblynx NV
- CzechiaCABLIVIAblynx NV, Zwijnaarde
- FinlandCabliviAblynx NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cablivi
- Liechtenstein · Cablivi
- Norway · Cablivi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/26a597b6-66c5-45f0-8866-5e60f70ea0ae GET /v1/drugs/26a597b6-66c5-45f0-8866-5e60f70ea0ae?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder and solvent for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Cablivi 10 mg",
"name_fr": "Cablivi 10 mg",
"name_nl": "Cablivi 10 mg",
"amp_code": "SAM534773-00",
"strengths": [
"10.0000",
"10.0000"
],
"pack_count": 3,
"substances": [
"Caplacizumab",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Caplacizumab",
"authorisation_numbers": [
"EU/1/18/1305/001",
"EU/1/18/1305/003",
"EU/1/18/1305/002"
]
}See everything about caplacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.